Chronic Cough

Chest X-ray film on a glowing light box
A chest X-ray is first-line imaging in any chronic cough.
Infographic: post-nasal drip, narrowed airway and acid reflux
In a non-smoker not taking an angiotensin-converting enzyme inhibitor, upper-airway cough syndrome, cough-variant asthma and reflux account for the great majority of chronic cough.
3D airway lining with a nerve signal travelling to the brainstem
Stimuli in the airway activate vagal nerves that signal the medulla in the brainstem to trigger the cough reflex.

Table of Contents

  1. Overview
  2. Types of Cough
  3. Common Causes
  4. Mechanisms
  5. Evaluation
  6. Management
  7. P2X3 Blockers in Clinical Trials
  8. When to Seek Medical Care
  9. Connections
  10. Key Research Papers
  11. Featured Videos

Overview

Chronic cough is defined as cough lasting more than eight weeks in adults (four weeks in children). It is one of the most common reasons for outpatient visits and one of the most under-evaluated. In a non-smoker not on an angiotensin-converting enzyme inhibitor (ACE inhibitor), the "big three" account for the great majority of cases: upper-airway cough syndrome (formerly post-nasal drip), cough-variant asthma, and gastroesophageal reflux. A systematic, sequential approach can resolve symptoms in most patients, while a smaller group with cough that resists this approach has "refractory chronic cough" driven by cough-reflex hypersensitivity, and benefits from neuromodulator therapy.

Chronic cough is common: a 2025 review gives adult chronic cough “a global prevalence of approximately 10%.” The same review describes refractory chronic cough as thought to arise from nerve dysregulation involving both peripheral and central mechanisms, called cough hypersensitivity syndrome, which is typically felt as a tickle or itch in the throat that leads to an urge to cough in response to seemingly harmless stimuli.

Types of Cough

Common Causes

Mechanisms

Evaluation

Management

P2X3 Blockers in Clinical Trials

P2X3 blockers are oral drugs that, as the 2020 ERS guideline describes them, tackle nerve hypersensitivity by blocking the excitability of the sensory (afferent) nerves at the ATP receptor P2X3. Trial results so far:

When to Seek Medical Care

Connections

Key Research Papers

Historical Background

The systematic study of chronic cough began with Irwin's 1981 anatomic-diagnostic protocol, which established the "big three" etiologies and a sequential approach. The European Respiratory Society and American College of Chest Physicians have since published a series of guidelines, and the conceptual framework has shifted from "identify the cause" to "identify the cough hypersensitivity phenotype." In 2022 the oral P2X3 receptor antagonist gefapixant became the first treatment to show efficacy with an acceptable safety profile in phase 3 trials for refractory chronic cough; a 2025 review reports it approved in the European Union, United Kingdom, Switzerland and Japan, though not in the United States or Canada.

Key Research Papers

  1. Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. American Review of Respiratory Disease. 1981;123(4 Pt 1):413-417. — PubMed PMID: 7224353
  2. Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. European Respiratory Journal. 2020;55(1):1901136. — doi:10.1183/13993003.01136-2019
  3. Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):1S-23S. — doi:10.1378/chest.129.1_suppl.1S
  4. McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2). The Lancet. 2022;399(10328):909-923. — doi:10.1016/s0140-6736(21)02348-5
  5. Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. Lancet Respiratory Medicine. 2013;1(5):414-422. — doi:10.1016/s2213-2600(13)70043-2
  6. Pratter MR. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):63S-71S. — doi:10.1378/chest.129.1_suppl.63S
  7. Dicpinigaitis PV. Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):75S-79S. — doi:10.1378/chest.129.1_suppl.75S
  8. Irwin RS. Chronic cough due to gastroesophageal reflux disease. Chest. 2006;129(1 Suppl):80S-94S. — doi:10.1378/chest.129.1_suppl.80S
  9. Vertigan AE, Theodoros DG, Gibson PG, Winkworth AL. Efficacy of speech pathology management for chronic cough: a randomised placebo-controlled trial. Thorax. 2006;61(12):1065-1069. — doi:10.1136/thx.2006.064337
  10. Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. The Lancet. 2012;380(9853):1583-1589. — doi:10.1016/S0140-6736(12)60776-4
  11. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S-173S. — doi:10.1378/chest.129.1_suppl.169S
  12. Peters AT, Altman KW, Dicpinigaitis P, et al. Therapeutic and mechanistic advances in chronic cough. Annals of Allergy, Asthma & Immunology. 2025;134(6):639-648. — doi:10.1016/j.anai.2024.12.021
  13. Yamamoto S, Horita N, Hara J, et al. Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough: Dose-Response Model-Based Network Meta-Analysis. Chest. 2024;166(5):1124-1140. — doi:10.1016/j.chest.2024.05.015
  14. Smith JA, Birring SS, Blaiss MS, et al. Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE). American Journal of Respiratory and Critical Care Medicine. 2025;211(6):1038-1048. — doi:10.1164/rccm.202409-1752OC

PubMed Topic Searches

  1. PubMed: Chronic cough evaluation
  2. PubMed: Cough-variant asthma
  3. PubMed: GERD and chronic cough
  4. PubMed: Cough hypersensitivity syndrome
  5. PubMed: Gefapixant and P2X3 antagonists for cough
  6. PubMed: ACE inhibitor cough

Back to Table of Contents

Chronic Cough — scientific infographic poster